BRPI0618529A2 - meio antiviral, abrangendo zeólitos ativados em forma tribomecánica, própolis e colostro - Google Patents

meio antiviral, abrangendo zeólitos ativados em forma tribomecánica, própolis e colostro Download PDF

Info

Publication number
BRPI0618529A2
BRPI0618529A2 BRPI0618529-0A BRPI0618529A BRPI0618529A2 BR PI0618529 A2 BRPI0618529 A2 BR PI0618529A2 BR PI0618529 A BRPI0618529 A BR PI0618529A BR PI0618529 A2 BRPI0618529 A2 BR PI0618529A2
Authority
BR
Brazil
Prior art keywords
fever
virus
hepatitis
agents
propolis
Prior art date
Application number
BRPI0618529-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Tihomir Lelas
Original Assignee
Tihomir Lelas
Mijo Ljubicic
Slavko Ivkovic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tihomir Lelas, Mijo Ljubicic, Slavko Ivkovic filed Critical Tihomir Lelas
Publication of BRPI0618529A2 publication Critical patent/BRPI0618529A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
BRPI0618529-0A 2005-11-11 2006-11-10 meio antiviral, abrangendo zeólitos ativados em forma tribomecánica, própolis e colostro BRPI0618529A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005054306 2005-11-11
DE102005054306.5 2005-11-11
PCT/DE2006/002008 WO2007054085A2 (de) 2005-11-11 2006-11-10 Antivirales mittel umfassend tribomechanisch aktiviertes zeolith (tmaz), propolis und kolostrum

Publications (1)

Publication Number Publication Date
BRPI0618529A2 true BRPI0618529A2 (pt) 2011-09-06

Family

ID=37763799

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0618529-0A BRPI0618529A2 (pt) 2005-11-11 2006-11-10 meio antiviral, abrangendo zeólitos ativados em forma tribomecánica, própolis e colostro

Country Status (2)

Country Link
BR (1) BRPI0618529A2 (de)
WO (1) WO2007054085A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR069539A1 (es) * 2007-07-25 2010-02-03 Tibotec Pharm Ltd Avances respecto de las formulaciones de comprimidos contra el vih
HRP20080158A2 (hr) * 2008-04-03 2009-10-31 Institut Ru�er Bo�kovi� Sastav i upotreba farmaceutskog pripravka za prevenciju i terapiju bolesti uzrokovanih infekcijama virusom herpes simplex tip 1 i herpes simplex tip 2
IT1401589B1 (it) * 2010-08-03 2013-07-26 Ecobase Gmbh Zeoliti ad azione neuroprotettiva.
ES2442773T3 (es) 2011-12-30 2014-02-13 Jakob Hraschan Prevención o tratamiento de polineuropatías dolorosas mediante la administración de un aluminosilicato
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
EP2870967A1 (de) * 2013-11-08 2015-05-13 Glock Health GmbH Behandlung entzündlicher Darmerkrankungen mit Klinoptilolith
EP3167890A1 (de) * 2015-11-12 2017-05-17 Glock Health, Science and Research GmbH Behandlung von vaginitis
CN110074978A (zh) * 2019-03-13 2019-08-02 安庆瑄宇医药科技有限公司 一种缬更昔洛韦组合片剂及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006002816A1 (de) * 2006-01-19 2007-07-26 Klinomed Institut für angewandte Nanotechnologie und Nanomedizin GmbH Mittel zur Therapie und Prophylaxe von HIV

Also Published As

Publication number Publication date
WO2007054085A2 (de) 2007-05-18
WO2007054085A3 (de) 2008-03-20

Similar Documents

Publication Publication Date Title
BRPI0618529A2 (pt) meio antiviral, abrangendo zeólitos ativados em forma tribomecánica, própolis e colostro
CN110325187B (zh) N-氨基甲酰亚胺基-5-(1-甲基-1h-吡唑-4-基)-2-萘甲酰胺在制备治疗流感的药物中的用途
EP1948196B1 (de) Verwendung von tetraorganosilizium-verbindungen
RU2745440C2 (ru) Способы и композиции для лечения ожирения, предотвращения прибавки массы, содействия снижению массы, содействия похудению или лечения или предотвращения развития диабета
TW200800230A (en) Composition and method related to fructosamine-3-kinase inhibitors
JP2020002167A (ja) 敗血症を処置するための方法および組成物
WO2010054531A1 (zh) 牛痘疫苗致炎兔皮提取物在制备急性脑血管疾病治疗药物中的用途
JP2000007570A (ja) 抗内分泌障害剤
JP2022501424A (ja) ４−アルキル−５−ヘテロアリール−３ｈ−１，２−ジチオール−３−チオンの回転異性体
JPS63500944A (ja) ウイルスの不活化
JP4285997B2 (ja) 性的機能不全を予防および治療するための医薬の製造におけるｎ−アセチル−ｄ−グルコサミンの使用
US20230190652A1 (en) Composition for the treatment of covid-19 and treatment method
JP2019529354A (ja) ナノシリカ粒子を含む組成物および療法のためにｔリンパ球を活性化する方法におけるそれらの使用
WO2012096596A1 (ru) Противовирусное средство
JP2002540150A (ja) ウイルス治療
CN113730584B (zh) 双硫仑联合铜补充剂在制备抗rna病毒的药物中的应用
CA2437168A1 (en) Retinoid hepatitis therapy
US20230071014A1 (en) Application of ritonavir in treating sars-cov-2 infection
AU2013254849B2 (en) Treatment method for steroid responsive dermatoses
US20230285442A1 (en) Use of oligochitosans and derivatives thereof for neutralizing viral agents
JP2000516962A (ja) ライノウイルス感染症の治療方法
BR102020014414A2 (pt) Formulação contendo análogo de nucleosídeo em associação com lisina para o tratamento e profilaxia do herpes
WO2021000417A1 (zh) 棕榈油酸用于制备预防或治疗炎症性疾病的组合物的用途
WO2022170845A1 (zh) 金纳米材料在抑制冠状病毒中的应用
WO2021186244A1 (en) Rotomeric isomers of 4-alkyl-5-heteroaryl-3h-1,2-dithiole-3-thiones

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.